Association between DPP‐4 inhibitor use and changes in dementia‐related plasma biomarkers in older adults with type 2 diabetes: post‐hoc analyses of J‐MINT

Abstract

Background: Preclinical studies suggest that dipeptidyl peptidase‐4 (DPP‐4) inhibitors reduce brain β‐amyloid (Aβ) deposition, tau phosphorylation, and neuroinflammation. However, human data remain limited.